{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:08:21Z","timestamp":1791209301978,"version":"4.1.0"},"reference-count":61,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The solubility advantage of an amorphous drug can be realized only when it releases at a sufficiently rapid rate from its amorphous solid dispersion (ASD). Herein, we evaluated the impact of a plasticizer, glyceryl tributyrate (GTB), on the release of a poorly soluble drug with a high glass transition temperature (Tg). Cyclosporine has a Tg of 124 \u00b0C and was formulated as an ASD with hydroxypropyl methylcellulose acetate succinate (HPMCAS). Binary and ternary ASDs were prepared using solvent evaporation, their Tgs were measured using differential scanning calorimetry, and surface area normalized release rates were determined. The drug-rich phase formed above the amorphous solubility was characterized for composition and size. Drug flux following release from the ASD was measured across Caco-2 cell monolayers. Cyclosporine released at a substantially faster rate from ternary ASDs containing GTB as compared to the corresponding binary ASD. This improvement was attributed to a decrease in Tg upon plasticization due to GTB increasing molecular mobility. Addition of GTB, however, reduced the amorphous solubility of cyclosporine resulting in a decrease in the transport rate across the Caco-2 cell monolayer. These observations may have implications for drug absorption. Ultimately, it is expected that the in vivo performance of these ternary ASDs would be determined by the interplay between the enhanced release rate and the decreased permeation rate of the drug.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00612","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:02:22Z","timestamp":1788544942000},"page":"5033-5043","source":"Crossref","is-referenced-by-count":0,"title":["Balancing Release and Permeation Rates in Cyclosporine Amorphous Solid Dispersions"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-208X","authenticated-orcid":true,"given":"Dishan D.","family":"Shah","sequence":"first","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-2929","authenticated-orcid":true,"given":"Gregory T.","family":"Knipp","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhan","family":"Yang","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Boston, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Marden","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Boston, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedong","family":"Wu","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Boston, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-6134","authenticated-orcid":true,"given":"Liping","family":"Zhou","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , ,","place":["Boston, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4568-6021","authenticated-orcid":true,"given":"Lynne S.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Purdue University , , , ,","place":["West Lafayette, Indiana, United States, 47907"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"11","key":"2026100509324816100_cit1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1248\/cpb.9.866","article-title":"Studies on Absorption of Eutectic Mixture. I. A Comparison of the Behavior of Eutectic Mixture of Sulfathiazole and that of Ordinary Sulfathiazole in Man","volume":"9","author":"Sekiguchi","year":"1961","journal-title":"Chem. Pharm. Bull."},{"issue":"10","key":"2026100509324816100_cit2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1021\/js980403l","article-title":"Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"2026100509324816100_cit3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1021\/mp800061r","article-title":"Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study","volume":"5","author":"Kennedy","year":"2008","journal-title":"Mol. Pharm."},{"issue":"1\u22122","key":"2026100509324816100_cit4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijpharm.2010.08.007","article-title":"Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach","volume":"399","author":"Onoue","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"9","key":"2026100509324816100_cit5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cpdd.1416","article-title":"Enhanced bioavailability and reduced variability of dasatinib and sorafenib with a novel amorphous solid dispersion technology platform","volume":"13","author":"Lennerna\u0308s","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"1\u22122","key":"2026100509324816100_cit6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijpharm.2017.10.051","article-title":"Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update","volume":"535","author":"Jermain","year":"2018","journal-title":"Int. J. Pharm."},{"key":"2026100509324816100_cit7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.xphs.2024.09.025","article-title":"Changes in drug crystallinity in a commercial tacrolimus amorphous formulation result in variable pharmacokinetics","volume":"114","author":"Taylor","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"2026100509324816100_cit8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0378-5173(01)00891-2","article-title":"The mechanisms of drug release from solid dispersions in water-soluble polymers","volume":"231","author":"Craig","year":"2002","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026100509324816100_cit9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1021\/acs.molpharmaceut.0c00790","article-title":"The influence of the strength of drug\u2212polymer interactions on the dissolution of amorphous solid dispersions","volume":"18","author":"Amponsah-Efah","year":"2020","journal-title":"Mol. Pharm."},{"key":"2026100509324816100_cit10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","article-title":"Physical chemistry of supersaturated solutions and implications for oral absorption","volume":"101","author":"Taylor","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"2026100509324816100_cit11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.xphs.2024.08.029","article-title":"Amorphous solubility advantage: theoretical considerations, experimental methods, and contemporary relevance","volume":"114","author":"Ueda","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"2026100509324816100_cit12","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1021\/acs.molpharmaceut.3c00526","article-title":"Crystallinity: a complex critical quality attribute of amorphous solid dispersions","volume":"20","author":"Moseson","year":"2023","journal-title":"Mol. Pharm."},{"issue":"4","key":"2026100509324816100_cit13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1021\/acs.molpharmaceut.9b01272","article-title":"Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition","volume":"17","author":"Saboo","year":"2020","journal-title":"Mol. Pharm."},{"issue":"1","key":"2026100509324816100_cit14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.xphs.2024.08.023","article-title":"Chemistry and ionization of HPMCAS influences the dissolution and solution-mediated crystallization of posaconazole amorphous solid dispersions","volume":"114","author":"Shah","year":"2025","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"2026100509324816100_cit15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejpb.2006.11.020","article-title":"Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug\u2212polymer interactions","volume":"66","author":"Karavas","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026100509324816100_cit16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2015.06.004","article-title":"Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers","volume":"211","author":"Sun","year":"2015","journal-title":"J. Control. Release"},{"issue":"2","key":"2026100509324816100_cit17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1021\/mp500660m","article-title":"Drug\u2212polymer\u2212water interaction and its implication for the dissolution performance of amorphous solid dispersions","volume":"12","author":"Chen","year":"2015","journal-title":"Mol. Pharm."},{"issue":"10","key":"2026100509324816100_cit18","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s11095-016-1969-2","article-title":"Initial drug dissolution from amorphous solid dispersions controlled by polymer dissolution and drug-polymer interaction","volume":"33","author":"Chen","year":"2016","journal-title":"Pharm. Res."},{"key":"2026100509324816100_cit19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2018.04.014","article-title":"Tailoring supersaturation from amorphous solid dispersions","volume":"279","author":"Li","year":"2018","journal-title":"J Control Release"},{"key":"2026100509324816100_cit20","doi-asserted-by":"publisher","first-page":"105514","DOI":"10.1016\/j.ejps.2020.105514","article-title":"Patterns of drug release as a function of drug loading from amorphous solid dispersions: A comparison of five different polymers","volume":"155","author":"Saboo","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"2026100509324816100_cit21","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1021\/acs.molpharmaceut.1c00055","article-title":"Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection","volume":"18","author":"Yang","year":"2021","journal-title":"Mol. Pharm."},{"issue":"6","key":"2026100509324816100_cit22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/jps.23979","article-title":"What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion?","volume":"103","author":"Frank","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"2026100509324816100_cit23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1208\/s12248-017-0052-1","article-title":"Advantageous solubility-permeability interplay when using amorphous solid dispersion (ASD) formulation for the BCS class IV P-gp substrate rifaximin: simultaneous increase of both the solubility and the permeability","volume":"19","author":"Beig","year":"2017","journal-title":"AAPS J."},{"key":"2026100509324816100_cit24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2018.11.003","article-title":"Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport","volume":"292","author":"Wilson","year":"2018","journal-title":"J Control Release"},{"issue":"1","key":"2026100509324816100_cit25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.molpharmaceut.8b01117","article-title":"Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements","volume":"16","author":"Hate","year":"2019","journal-title":"Mol Pharm"},{"key":"2026100509324816100_cit26","doi-asserted-by":"publisher","first-page":"121174","DOI":"10.1016\/j.ijpharm.2021.121174","article-title":"Predicting in vivo performance of fenofibrate amorphous solid dispersions using in vitro non-sink dissolution and dissolution permeation setup","volume":"610","author":"Lentz","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"12","key":"2026100509324816100_cit27","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1021\/acs.molpharmaceut.9b01025","article-title":"Insights into the Dissolution Behavior of Ledipasvir-Copovidone Amorphous Solid Dispersions: Role of Drug Loading and Intermolecular Interactions","volume":"16","author":"Que","year":"2019","journal-title":"Mol Pharm"},{"key":"2026100509324816100_cit28","doi-asserted-by":"publisher","first-page":"122120","DOI":"10.1016\/j.ijpharm.2022.122120","article-title":"Role of surfactants in improving release from higher drug loading amorphous solid dispersions","volume":"625","author":"Correa-Soto","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"3","key":"2026100509324816100_cit29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11095-023-03483-3","article-title":"Release Enhancement by Plasticizer Inclusion for Amorphous Solid Dispersions Containing High T(g) Drugs","volume":"40","author":"Correa-Soto","year":"2023","journal-title":"Pharm. Res."},{"issue":"2","key":"2026100509324816100_cit30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2006.08.010","article-title":"Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer\u2212surfactant combinations using solubility parameters and testing the processability","volume":"328","author":"Ghebremeskel","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"12","key":"2026100509324816100_cit31","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1007\/s11095-023-03502-3","article-title":"Drug Release from Surfactant-Containing Amorphous Solid Dispersions: Mechanism and Role of Surfactant in Release Enhancement","volume":"40","author":"Yang","year":"2023","journal-title":"Pharm. Res."},{"issue":"5","key":"2026100509324816100_cit32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/pharmaceutics13050735","article-title":"Exploring the Role of Surfactants in Enhancing Drug Release from Amorphous Solid Dispersions at Higher Drug Loadings","volume":"13","author":"Saboo","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026100509324816100_cit33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jconrel.2020.01.031","article-title":"Mechanistic insights into effect of surfactants on oral bioavailability of amorphous solid dispersions","volume":"320","author":"Schittny","year":"2020","journal-title":"J. Control. Release"},{"issue":"2","key":"2026100509324816100_cit34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11095-022-03183-4","article-title":"Role of Surfactants on Release Performance of Amorphous Solid Dispersions of Ritonavir and Copovidone","volume":"39","author":"Indulkar","year":"2022","journal-title":"Pharm. Res."},{"issue":"4","key":"2026100509324816100_cit35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.xphs.2018.10.058","article-title":"Effects of surfactants on itraconazole-HPMCAS solid dispersion prepared by hot-melt extrusion I: miscibility and drug release","volume":"108","author":"Solanki","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"2026100509324816100_cit36","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1021\/acs.cgd.5c00417","article-title":"Impact of Surfactants as Formulation Additives and Media Components on the Performance of Amorphous Solid Dispersions","volume":"25","author":"Zhang","year":"2025","journal-title":"Cryst. Growth Des."},{"issue":"9","key":"2026100509324816100_cit37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/pharmaceutics17091090","article-title":"Continuous Processing Strategies for Amorphous Solid Dispersions of Itraconazole: Impact of Polymer Selection and Manufacturing Techniques","volume":"17","author":"Kshirsagar","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026100509324816100_cit38","doi-asserted-by":"publisher","first-page":"100259","DOI":"10.1016\/j.ijpx.2024.100259","article-title":"Trends in amorphous solid dispersion drug products approved by the US Food and Drug Administration between 2012 and 2023","volume":"7","author":"Moseson","year":"2024","journal-title":"Int. J. Pharm.:X"},{"issue":"12","key":"2026100509324816100_cit39","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1016\/j.xphs.2018.08.002","article-title":"A new hydrate of cyclosporine: structural and physicochemical characterization","volume":"107","author":"Wu","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"2026100509324816100_cit40","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1208\/s12249-018-1080-6","article-title":"Effects of dendrimer-like biopolymers on physical stability of amorphous solid dispersions and drug permeability across Caco-2 cell monolayers","volume":"19","author":"Lavan","year":"2018","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"2026100509324816100_cit41","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/jps.23241","article-title":"The effects of intralaboratory modifications to media composition and cell source on the expression of pharmaceutically relevant transporters and metabolizing genes in the Caco-2 cell line","volume":"101","author":"Roth","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"2026100509324816100_cit42","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1021\/js9700309","article-title":"Paracellular diffusion in Caco-2 cell monolayers: Effect of perturbation on the transport of hydrophilic compounds that vary in charge and size","volume":"86","author":"Knipp","year":"1997","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"2026100509324816100_cit43","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1124\/jpet.105.087148","article-title":"Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1\/Madin-Darby canine kidney clones and Caco-2 cells","volume":"314","author":"Bhardwaj","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"2026100509324816100_cit44","doi-asserted-by":"publisher","first-page":"8272","DOI":"10.1021\/acs.jmedchem.1c00211","article-title":"Interplay among conformation, intramolecular hydrogen bonds, and chameleonicity in the membrane permeability and cyclophilin A binding of macrocyclic peptide cyclosporin O derivatives","volume":"64","author":"Lee","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026100509324816100_cit45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/a:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"issue":"12","key":"2026100509324816100_cit46","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"2026100509324816100_cit47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"issue":"11","key":"2026100509324816100_cit48","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s12272-010-1116-2","article-title":"Biowaiver extension potential and IVIVC for BCS class II drugs by formulation design: case study for cyclosporine self-microemulsifying formulation","volume":"33","author":"Yang","year":"2010","journal-title":"Arch. Pharmacal Res."},{"issue":"3","key":"2026100509324816100_cit49","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ejpb.2013.08.003","article-title":"Supersaturated polymeric micelles for oral cyclosporine A delivery","volume":"85","author":"Yu","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026100509324816100_cit50","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2147\/ijn.s357541","article-title":"The effect of particle size on the absorption of cyclosporin a nanosuspensions","volume":"17","author":"Sun","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"2026100509324816100_cit51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.xphs.2018.11.003","article-title":"Enabling an HCV treatment revolution and the frontiers of solid solution formulation","volume":"108","author":"McKelvey","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"2026100509324816100_cit52","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1021\/mp400228x","article-title":"Influence of additives on the properties of nanodroplets formed in highly supersaturated aqueous solutions of ritonavir","volume":"10","author":"Ilevbare","year":"2013","journal-title":"Mol Pharm"},{"issue":"25","key":"2026100509324816100_cit53","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.1021\/ma00129a012","article-title":"Study of solvent diffusion in polymeric materials using magnetic resonance imaging","volume":"28","author":"Ercken","year":"1995","journal-title":"Macromolecules"},{"issue":"16","key":"2026100509324816100_cit54","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pen.760221603","article-title":"Diffusion and localized swelling resistances in glassy polymers","volume":"22","author":"Gostoli","year":"1982","journal-title":"Polym. Eng. Sci."},{"issue":"8","key":"2026100509324816100_cit55","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/s0079-6700(03)00045-5","article-title":"A review of polymer dissolution","volume":"28","author":"Miller-Chou","year":"2003","journal-title":"Prog. Polym. Sci."},{"issue":"2\u22123","key":"2026100509324816100_cit56","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/s0376-7388(00)81415-5","article-title":"Diffusion of organic vapors at low concentrations in glassy PVC, polystyrene, and PMMA","volume":"10","author":"Berens","year":"1982","journal-title":"J. Membr. Sci."},{"issue":"10","key":"2026100509324816100_cit57","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jps.10205","article-title":"Water vapor absorption into amorphous hydrophobic drug\/poly (vinylpyrrolidone) dispersions","volume":"91","author":"Crowley","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"2026100509324816100_cit58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-026-01407-5","article-title":"The expanding role of formulations to enable oral delivery of poorly water-soluble drugs","volume":"25","author":"Ueda","year":"2026","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"9","key":"2026100509324816100_cit59","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1021\/acs.molpharmaceut.2c00565","article-title":"Comparisons of in Vitro Models to Evaluate the Membrane Permeability of Amorphous Drug Nanoparticles","volume":"19","author":"Sabra","year":"2022","journal-title":"Mol Pharm"},{"issue":"3","key":"2026100509324816100_cit60","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1021\/la0523661","article-title":"Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening","volume":"22","author":"Lindfors","year":"2006","journal-title":"Langmuir"},{"issue":"1","key":"2026100509324816100_cit61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.xphs.2018.09.031","article-title":"Mechanistic study of belinostat oral absorption from spray-dried dispersions","volume":"108","author":"Stewart","year":"2019","journal-title":"J. Pharm. Sci."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00612","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5033\/68385375\/mp6c00612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5033\/68385375\/mp6c00612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:26Z","timestamp":1791208166000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/5033\/5421268\/Balancing-Release-and-Permeation-Rates-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,4]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00612","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}